Assistant Professor @VAAnnArbor @UMRogelCancer Lung and H&N onc | Pharmacoecon @VA_CCMR | @OCCA_Cancer | Views mine
Ann Arbor, MI
Joined December 2012
- Tweets391
- Following134
- Followers199
- Likes655
Garth Strohbehn retweeted
The tyranny of non-inferiority trials
thelancet.com/journals/lanon…
Garth Strohbehn retweeted
This is a brilliant and poignant piece highlighting patient perspectives on overtreatment, clinical trials, and quality of life. I hope many patients read this. evidence.nejm.org/doi/full/1…
Garth Strohbehn retweeted
So @FDAOncology @US_FDA approves peri operative Durvalumab for resectable NSCLC.
1 - We know there is NO Os benifit for this as of now .
2 - We know that we don't know what is the benifit of adjuvant Durvalumab over neoadjuvant Durvalumab alone .
3 - We know that we need better trial designs in perioperative space.
( which we will never have )
4 - We know that pembrolizumab is already approved in this setting and has shown OS benifit .
5 - And lastly we know that neo adjuvant Nivo alone is probably the most cost effective of all the approved strategies in this space as of today .
Updated OS data from Aegean Trial. After censoring for deaths due to covid 19 - HR for OS is 0.85 ( CI - 0.64 to 1.12 ) . Note that FDA has suggested in its own document that even if OS is demonstrated, it will not show contribution of Neoadjuvant component vs Adjuvant component seperatly . FDA has suggested new designs for future peri operative trials .
ODAC votes on July 25 th on these questions. @VPrasadMDMPH @FordePatrick @Timothee_MD @oncology_bg @JackWestMD @DrJNaidoo @PatelOncology @RManochakian @n8pennell
Garth Strohbehn retweeted
We may be living through an unprecedented nightmare hellscape for morality, crime, happiness, the economy, music, movies, science, sports and more.
But at least we can take some solace that we’re living in the golden age of data journalism.
By @andrewvandam
Garth Strohbehn retweeted
NEWS: I sent a letter to Amgen to investigate the pharma co’s decisions on its cancer drug—after FDA review & new studies suggest its dosing level may be excessive, exposing cancer patients to unnecessarily high costs & harsh side effects from the company’s 8-pill daily dosage.
Thanks for amplifying @SuyogCancer
The mandated dose optimization trial is complete. There’s no advantage to 960.
Optimal dose . Cost of the tablet . Size of the tablet . Sotorasib dosing and Incremental Cost ineffectiveness.
Does this ring bell 🔔 for other oral drugs also? Lorlatinib ? , lapatinib , Abemaciclib ?? , Abiraterone . Comment in @NatRevClinOncol by @garthstrohbehn and Mark Ratain. @VPrasadMDMPH
Garth Strohbehn retweeted
A new review suggests that many cancer drugs are interchangeable, which could potentially lead to significant cost savings for patients and health systems.
@drdgoldstein
bmjoncology.bmj.com/content/…
Garth Strohbehn retweeted
In a Comment now published online, @garthstrohbehn & Mark J. Ratain discuss the implications of results recently discussed in a recent @FDAOncology Oncologic Drugs Advisory Committee meeting on sotorasib dosing and the implications for stakeholders nature.com/articles/s41571-0…
Garth Strohbehn retweeted
Access to immunotherapy can be improved in India. We have 100% access at our hospital. It is not possible without low dose and/or mg/kg dose regimens. Access and rationalization of resources can be addressed simultaneously.
ascopubs.org/doi/abs/10.1200…
Garth Strohbehn retweeted
Great commentry by @oncology_bg and @garthstrohbehn . Immunotherapy in prepatients -preventing or promoting a malignant transformation? . Thought proving commentry in @JAMAOnc . Full article for those who do not have access.
Hot off the press! In this new editorial with @garthstrohbehn now out in @JAMAOnc , we caution against ever expanding use of drugs in ever earlier lines of therapy. Are we ready to move immunotherapy use from treating cancers to treating risk factors for cancer? jamanetwork.com/journals/jam…
Garth Strohbehn retweeted
Hot off the press! In this new editorial with @garthstrohbehn now out in @JAMAOnc , we caution against ever expanding use of drugs in ever earlier lines of therapy. Are we ready to move immunotherapy use from treating cancers to treating risk factors for cancer? jamanetwork.com/journals/jam…
Garth Strohbehn retweeted
MedTwitter - take note👇
If you can't muster a simple retweet to:
Denounce terrorism
&
Offer sympathy and support for dead Jews
...Then there's something profoundly wrong with your sense of justice.
...And your previous advocacy efforts for any marginalized group were empty and fake
All Jews are under attack, because all Jews are one family. Hamas killed over 1,000 Jews bec they were Jews- it has nothing to do with politics. Hamas butchered innocent Jewish men, women, children and babies in the most unimaginable horrific fashion
Pls follow these accounts who can easily be retweeted to show your support -
@Israel
@HenMazzig
@Ostrov_A
@IDF
#IsraelUnderAttack
Garth Strohbehn retweeted
Please join us in reading out latest publication in @NatureMedicine, discussing dose optimization for ICI to allow global access.
Thank you to all the co-authors for their guidance: Dr. Gilbert, @MarcusButler_PM, @drdgoldstein and Dr. Tannock
nature.com/articles/s41591-0…
Garth Strohbehn retweeted
.@OCCA_Cancer: "It is highly likely that CodeBreak 201 will show that the therapeutic index of sotorasib 240mg daily is superior to that of sotorasib 960 mg daily. Given this probable result, we suggest that the FDA should not grant full approval."
cancerletter.com/guest-edito…
Garth Strohbehn retweeted
Retrospective cohort study of extended-interval dosing comprised minority of pembrolizumab monotherapy use despite @US_FDA approval & potential societal benefits, but clinical data show equivalence of time to treatment discontinuation across indications. ja.ma/3fbK7qA
Garth Strohbehn retweeted
Grant reviews have always been tough. Here's how I imagine an ancient proposal to discover coffee would have been reviewed.
#AcademicTwitter @OpenAcademics @AcademicChatter
Garth Strohbehn retweeted
There it is - Unanimously approved by Senate Judiciary Committee. A solid step forward for patients! @SenatorDurbin @ChuckGrassley
NEW: BIPARTISAN Senate bill to enhance collaboration between FDA and the US Patent and Trademark Office introduced, inspired by OCCA work grassley.senate.gov/news/new…
Garth Strohbehn retweeted
New 🔥🔥🔥 from @OCCA_Cancer’s Dr Mark Ratain in @JCOOP_ASCO
ascopubs.org/doi/abs/10.1200…
“Oncology Drug Prescribing: The Influences of Greed and Fear”
Garth Strohbehn retweeted
NEW: BIPARTISAN Senate bill to enhance collaboration between FDA and the US Patent and Trademark Office introduced, inspired by OCCA work grassley.senate.gov/news/new…
Garth Strohbehn retweeted
A huge thanks to all participants in yesterday’s @OCCA_Cancer Clinical Trials Update! We had representation from: 🇮🇳🇳🇱🇬🇧🇺🇸🇸🇬🇨🇦🇯🇵🇫🇷🇵🇰🇧🇪🇪🇸🇮🇹🇦🇷🇮🇸🇮🇱🇭🇰🇨🇴🇦🇺🇸🇪. And if we’re ever going to solve this 🌎 problem of overdosing we need 🌎 solutions!